The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies
João Castelhano, Gisela Lima, Marta Teixeira, Carla Soares, Marta Lapo Pais, Miguel Castelo-Branco
Frontiers in Pharmacology September 29, 2021 DOI: 10.3389/fphar.2021.739053 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review and meta-analysis Peer reviewed |
|---|---|
| Topics | Psilocybin Serotonin |
| Keywords | Hallucinogen Anterior cingulate cortex Posterior cingulate Dorsolateral prefrontal cortex Temporal cortex 5-HT Receptor Ventromedial prefrontal cortex Functional imaging Cortex anatomy Cognition |
| Citations | 34 |
| Key findings | Tryptamine psychedelics produce robust neuromodulatory effects in brain regions involved in mental imagery, theory of mind, and affective regulation, particularly those with high 5HT2A receptor density, including visual cortex, cingulate cortex, medial prefrontal cortex, and the right amygdala. |
Abstract
There is an increasing interest in the neural effects of psychoactive drugs, in particular tryptamine psychedelics, which has been incremented by the proposal that they have potential therapeutic benefits, based on their molecular mimicry of serotonin. It is widely believed that they act mainly through 5HT2A receptors but their effects on neural activation of distinct brain systems are not fully understood. We performed a quantitative meta-analysis of brain imaging studies to investigate the effects of substances within this class (e.g., LSD, Psilocybin, DMT, Ayahuasca) in the brain from a molecular and functional point of view. We investigated the question whether the changes in activation patterns and connectivity map into regions with larger 5HT1A/5HT2A receptor binding, as expected from indolaemine hallucinogens (in spite of the often reported emphasis only on 5HT2AR). We did indeed find that regions with changed connectivity and/or activation patterns match regions with high density of 5HT2A receptors, namely visual BA19, visual fusiform regions in BA37, dorsal anterior and posterior cingulate cortex, medial prefrontal cortex, and regions involved in theory of mind such as the surpramarginal gyrus, and temporal cortex (rich in 5HT1A receptors). However, we also found relevant patterns in other brain regions such as dorsolateral prefrontal cortex. Moreover, many of the above-mentioned regions also have a significant density of both 5HT1A/5HT2A receptors, and available PET studies on the effects of psychedelics on receptor occupancy are still quite scarce, precluding a metanalytic approach. Finally, we found a robust neuromodulatory effect in the right amygdala. In sum, the available evidence points towards strong neuromodulatory effects of tryptamine psychedelics in key brain regions involved in mental imagery, theory of mind and affective regulation, pointing to potential therapeutic applications of this class of substances.
Comparable studies
Other systematic reviews and meta-analyses on serotonin, most cited first.
Citations in the library
Cited by 28
- Sustained effects of single doses of classical psychedelics in humans. Neuropsychopharmacology June 21, 2022
- Psychedelics in the treatment of unipolar and bipolar depression International Journal of Bipolar Disorders July 5, 2022
- If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics. Journal of Pain October 1, 2022
- Role of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and psychedelics in the treatment of major depressive disorder: A perspective on mechanistic insight and current status. European Journal of Pharmacology August 15, 2025
- Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review Chronic Stress 2022
and 23 more in the library
Cites 78
- Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry 2003
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Proceedings of the National Academy of Sciences January 23, 2012
and 73 more in the library